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ABSTRACT
Introduction. Respiratory syncytial virus (RSV) 
is the major causative organism associated 
with acute lower respiratory tract infections 
in children.The objective of this study was to 
describe the clinical and epidemiological pattern 
of RSV and identify risk factors for RSV infection.
Population and Methods. Prospective, cohort 
study on patients hospitalized due to acute lower 
respiratory tract infection at Hospital de Niños 
Ricardo Gutiérrez between March and November 
throughout the 2000-2013 period. The virological 
diagnosis of RSV, adenovirus, influenza and 
parainfluenza was performed by indirect 
immunofluorescence using nasopharyngeal 
aspirates.
Results. A total of 12 555 children were included, 
38.2% (4798) had virus rescued from samples. 
RSV accounted for 81.8% of cases (3924/4798) 
with no significant annual variations (71.2-
88.1) and with an epidemic seasonal pattern 
(May through July); RSV was followed by 
influenza (7.6%), parainfluenza (5.9%), and 
adenovirus (4.7%).The median age of patients 
with RSV rescue (3924) was 7 months old (0-
214 months old), while 74.2% were younger 
than 1 year old, 43.1% were younger than 
6 months old, 56.5% were males and the most 
common clinical presentation was bronchiolitis 
(60.7%). Comorbidities were observed in 41.6% 
of cases. The most common comorbidities were 
chronic respiratory disease (74%), congenital 
heart disease (14%), and chronic neurological 
disease (10.2%).Complications occurred in 25% 
of cases. The case fatality rate was 1.9% (74/3888).
Independent predictors of RSV infection were 
age <3 months old (OR: 2.8 [2.14-3.67], p < 0.01), 
clinical presentation of bronchiolitis (OR: 1.54 
[1.32-1.79], p < 0.01), and hypoxemia at the time 
of admission (OR: 1.84 [1.42-2.37], p < 0.01).
Conclusions. RSV infection displayed a seasonal 
pattern and was associated with infants younger 
than 3 months old with bronchiolitis and 
hypoxemia at the time of admission.
Key words: respiratory syncytial virus,bronchiolitis, 
epidemiology.
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INTRODUCTION
Acute lower respiratory tract 
infections (ALRTIs)in children are 
one of the most common reasons 
for medical consultation, school 
absenteeism, hospitalizations and 
child mortality.1,2 Mortality is higher 
in developing countries in comparison 
with developed countries, especially 
in children younger than 5 years old.3 
In Argentina, according to the 
latest report by the Ministry of Health 
(December 2012), respiratory diseases 
were the third cause of mortality in 
children younger than 5 years old (after 
perinatal conditions and congenital 
anomalies) and accounted for 6.3% 
(572/9037) of all deaths for a definite 
cause in this age group in 2012.4 
Viruses are the most common 
pathogens involved in ALRTIs, 
as shown in several national and 
international publications.1-5 
T h e  r e c o m m e n d e d  r a p i d 
diagnostic method for the detection of 
respiratory viruses is usually indirect 
immunofluorescence (IIF).This has 
been a widely used technique due 
to its swiftness, low cost, simplicity, 
adequate specificity and sensitivity. 
IIF allows to identify viral agents 
generally related to ALRTIs, such 
as respiratory syncytial virus (RSV), 
i n f l u e n z a ,  p a r a i n f l u e n z a ,  a n d 
adenovirus.6-10 
The rapid identification of viral 
etiologic agents is essential for the 
epidemiological  monitor ing of 
this condition, it helps to reduce 
the unnecessary use of antibiotics 
and, as a result, decreases bacterial 
resistance, therefore improving the 
care provided to hospitalized patients 
and optimizing available resources. In 
addition, it enables to adopt measures 
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aimed at reducing nosocomial transmission by 
implementing contact or respiratory isolation 
measures as appropriate.
Although in the past years, a large number of 
studies have been conducted to assess molecular 
techniques for the diagnosis of respiratory 
virus, IIF is still the technique of choice in the 
case of RSV, the object of this study, due to 
its high sensitivity and specificity, which is 
not the case with other respiratory viruses 
(adenovirus). Detection sensitivity through 
molecular techniques has increased between 4% 
and 7%.10 Even in the “PCR era”, IIF is a method 
especially adapted for the ongoing surveillance 
for local epidemiology of respiratory viruses in 
the pediatric population.9 
Particularly, RSV is the major pathogen 
causing bronchiolitis and pneumonia in young 
infants, and different epidemiological studies 
have shown that the primary RSV infection takes 
place between 6 weeks of age and 2 years old.2,11-17 
Given the magnitude of the problem caused 
by ALRTIs, it is important to describe their 
clinical and epidemiological pattern and the 
burden of RSV in our setting and identify risk 
factors for RSV infection. In the future, this 
information would allow to have data to work 
on the prevention of RSV infection with specific 
vaccines and optimize administration schedules 
and ages, and then evaluate their effectiveness 
and adjust health policies accordingly.18 
The objective of this study was to describe the 
clinical and epidemiological pattern of RSV and 
identify risk factors for RSV infection.
POPULATION AND METHODS
This was an analytical, epidemiological, 
and prospective cohort study. All patients 
hospitalized due to ALRTIs, detected through 
the Epidemiological Surveillance Program (PVE, 
Programa de Vigilancia Epidemiológica) for ALRTIs 
of Hospital de Niños RicardoGutiérrez between 
March and November throughout the 2000-
2013 period (14 years) were included. Patients 
with ALRTI with RSV rescue confirmed to have 
been hospital-acquired were excluded.
The Epidemiological Surveillance Program 
conducts an active surveillance of patients 
hospitalized due to ALRTIs (first-time or recurrent 
episodes of bronchial obstruction in infants 
younger than 2 years old and pneumonias in any 
age group). In our study, patients hospitalized 
due to ALRTIs with RSV rescue were included. 
Data were collected in an epidemiological card, 
including date of admission, demographic 
data, age, sex, origin, clinical presentation 
(bronchiolitis, pneumonia), prior hospitalizations 
related to a respiratory condition, readmissions 
due to a recurrent episode, comorbidities, 
presence of household members with probable 
viral acute respiratory disease (rhinorrhea, 
cough and/or fever) or close contact with such 
condition, perinatal history, complications during 
hospitalization, clinical course (discharge, transfer 
to a different facility, death), treatment, and length 
of stay.Comorbidities were defined as chronic 
or recurrent respiratory disease, malnutrition, 
congenital heart disease, genetic condition, 
neurological disease, and immunosuppression.
The presence of any of the following conditions 
was recorded as chronic or recurrent respiratory 
disease:recurrent obstructive bronchitis (ROB) or 
asthma, gastroesophageal reflux, cystic fibrosis 
of the pancreas, bronchopulmonary dysplasia, 
recurrent pneumonia, and recurrent laryngitis. 
ROB was defined as the occurrence of two or more 
bronchoobstructive episodes.The following were 
recorded as complications: otitis, pneumothorax, 
persistent atelectasis,  sepsis,  respiratory 
failure, and nosocomial infection. Nosocomial 
infection was defined as an acute exacerbation 
of the respiratory condition, manifested as fever, 
increased oxygen requirement, or changes in the 
radiological pattern, present in included patients 
as of 48 hours of hospitalization and that was 
absent at the time of admission.
Diagnostic Methods
The clinical or radiological diagnosis of 
bronchiolitis and pneumonia was performed in 
compliance with the Guidelines of the Sociedad 
Argentina de Pediatría.1 The virological diagnosis 
was performed through IIF using nasopharyngeal 
aspirates collected in the first 24 hours of 
hospitalization. Samples were obtained using a 
K-30 nasogastric tube introduced through the 
nose and submitted immediately to the hospital’s 
Laboratory of Virology.For antigen detection in 
aspirate cells, the IIF rapid diagnostic method 
was used. Samples were washed in buffer saline 
solutionand cells were separated by centrifugation 
and then placed on a microscope slide and 
fixed with acetone. The following respiratory 
viruses were looked for: RSV, adenovirus, 
influenza A and B, and parainfluenza 1, 2 and 3 
with monoclonal antibodies (Chemicon, USA).
Immunofluorescence was revealed with the 
corresponding anti-species sera.
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For genotyping, the ectodomain of the RSV 
G glycoprotein was sequenced because it is one 
of the main surface glycoproteins that lead to 
the development of neutralizing antibodies.
Nucleic acids were extracted directly from 
nasopharyngeal aspirates using the NucleoSpin® 
RNA/Protein (Machery-Nagel) kit following 
the manufacturer’s instructions.RNA was 
then retrotranscribed and amplified using the 
Qiagen-OneStep RT-PCR (Qiagen) kit following 
the manufacturer’s instructions and using the 
primers specified for the above mentioned region. 
Subsequently, a bidirectional sequencing was 
performed on PCR purified products using the 
BigDye Terminator v3.1 (Applied Biosystems) 
kit in the ABI3500 genetic analyzer (Applied 
Biosystems).
Data Analysis
The statistical analysis was done using the 
Epi Info software version 7 (CDC, Atlanta, USA).
Qualitative outcome measures were analyzed 
usingYates correctedc2 test. The relative risk (RR) 
was considered the measure of association, with 
a 95% confidence interval (CI). A multivariate 
analysis was conducted to establish independent 
predictors, using the logistic regression model 
of the SPSS software version 15.0 for qualitative 
outcome measures. A value of p < 0.05 was 
considered significant.
RESULTS
A total of 12 555 children were included, 38.2% 
(4798) had some virus rescued from samples. This 
is the population to be analyzed in the study.
RSV accounted for 81.8% (3924/4798) of 
positive samples. A very low incidence was 
observed for the rest of the identified viruses: 
influenza accounted for 7.6% (365/4798) of cases, 
parainfluenza, 5.9% (282/4798), and adenovirus, 
4.7% (227/4798). The annual distribution of 
ALRTIs due to RSV was 2000: 84.8%; 2001: 71.2%; 
2002: 79.8%; 2003: 74.7%; 2004: 87.4%; 2005: 84.4%; 
2006: 88.1%; 2007: 78.0%; 2008: 81.2%; 2009: 77.6%; 
2010: 87.3%; 2011: 82.8%; 2012: 84.7%; 2013: 71.5% 
(peak May through July) (Figure 1). In 2009, 
during the H1N1 influenza A virus pandemic, 
RSV was displaced by this pandemic virus 
throughout the highest circulation period.
The highest incidence of ALRTIs due to RSV 
was predominant between epidemiological weeks 
(EW) 25 and 30 (June-July), except in 2010 and 
2012, when peaks presenting as earlier as EW 18 
(May) (Figure 2). The annual hospital incidence 
rate for bronchiolitis was 39.1/1000 (2003 peak: 
47.8/1000), while for bronchiolitis due to RSV, it 
was 15.4/1000 (8-19.4) with a seasonal epidemic 
pattern (May through July).
The median age of patients hospitalized with a 
diagnosis of ALRTI due to RSV was 7 months old 
(0-216 months old). Of them, 10% were younger 
Figure 1. Annual distribution of respiratory viruses in children hospitalized due to acute lower respiratory tract infection at 
Hospital de Niños R. Gutiérrez,” 2000-2013
Adenovirus
RSV
PIF
INF B
INF A
RSV: respiratory syncytial virus. PIF: parainfluenza. INF B: influenza B. INF A: influenza A.
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bronchiolitis, and hypoxemia at the time of 
admission (Table 3).
The analysis of genotypic characteristics 
of RSV strains in hospitalized patients during 
the study period (2000-2012) disclosed two 
RSV subtypes,A and B, which have circulated 
concurrently in the pediatric population. 
Subtype A was observed every year included 
in the analysis period, except in 2005, when 
only subtype B was found in analyzed samples. 
However, subtype A was the only one identified 
in 2000. Genotypic characteristics of subtype B 
showed genotype BA with a duplication of 
20 amino acids in G glycoprotein in relation to 
the reference strain of RSV, B/CH18537/63, 
than 2 months old, 43.1% were younger than 
6 months old, and 74.2% were younger than 
1 year old; 56.5% were males. The most common 
clinical presentation was bronchiolitis, with 60.7% 
of cases, while the other 39.3% corresponded to 
pneumonia. Forty-eight percent of patients had 
a history of intrafamilial contact or close contact 
with acutely-ill individuals.
Readmiss ions  due  to  the  same event 
corresponded to 3.2% of cases, while prior 
hospitalizations for a respiratory condition 
corresponded to 26.9%. Of these patients, 41.6% 
had concomitant pathologies. The most common 
were chronic respiratory disease (CRD) (74%), 
congenital heart disease (14%), prematurity 
(13.6%), chronic neurological disease (10.2%), 
malnutrition (5.1%), and immunosuppression 
(1.9%).  Recurrent obstructive bronchitis 
accounted for 94% of all recorded CRDs (Table 1).
The median hospital length of stay was 
7 days (1-200 days). Complications during 
hospitalization occurred in 25% of cases (Table 2). 
Intensive care with mechanical ventilation due 
to respiratory failure was required in 6.9% of 
patients. Nosocomial infections were present in 
6.6% of patients. The case fatality rate was 1.9% 
(74/3888).
Risk factors associated with RSV infection 
compared to other viruses were age younger 
than 3 months old, clinical presentation of 
Figure 2. Temporal series of respiratory syncytial virus cases in children hospitalized due to acute lower respiratory tract 
infection at Hospital de Niños R. Gutiérrez, 2000-2013
Table 1. Chronic respiratory disease, distribution by 
pathology
Chronic respiratory disease (n= 1204)
 n %
Recurrent obstructive bronchitis -  
Asthma 1115 94
Recurrent pneumonia 31 2.6
Gastroesophageal reflux 18 1.5
Bronchopulmonary dysplasia 13 1.2
Cystic fibrosis of the pancreas 5 0.4
Recurrent laryngitis 4 0.3
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circulating in our region, which had a duplication 
of 24 amino acids in G glycoprotein, and was 
called genotype ON1.
DISCUSSION
ALRTIs are an important cause of morbidity 
and mortality, medical consultations and 
hospitalizations in the first years of life.
RSV was the viral agent most commonly 
identified in our population as the cause of 
ALRTIs. This finding is consistent with data 
published in the international literature.21-25 
During the 14-year period of our study, RSV was 
predominant over other circulating viruses, even 
in 2009, year of the H1N1 influenza A pandemic. 
Although RSV was displaced during the peak 
circulation of H1N1 that year, the total number 
of ALRTIs due to RSV was higher than the total 
number of H1N1 cases.
The analysis of the genotypic characteristics 
of RSV strains indicates that it is likely that 
the virus’ plasticity allows it to adapt to such 
drastic changes on its surface proteins, granting 
it evolutionary advantages that allow it to 
undermine the previously generated immune 
response; this way, RSV is able to circulate in 
the pediatric population and continue to be the 
most commonly observed viral agent in infants 
younger than 1 year old with ALRTIs.
In mild climate regions, RSV is markedly 
seasonal and characterized by the occurrence of 
an annual outbreak during months of the lowest 
temperature. We clearly and objectively identified 
RSV seasonality, predominant between May 
and July and with annual differences in terms of 
magnitude and time of onset of the outbreak.
Differences in relation to the magnitude of 
annual RSV outbreaks have been observed, 
which led to describing RSV as having “biannual 
cycles,” with early major outbreaks alternating 
with later minor ones.1
Such biannual cyclic pattern was first 
described in Europe; in our 14-year study, this 
alternation was corroborated in the past five 
years, similar to what has been described by 
different studies.26,27 The value of these data is 
still limited, but if cycles were confirmed to be 
regular, data would become vitally significant for 
planning health actions.1
The largest RSV outbreak occurred in 2003, 
although major outbreaks were also observed 
in 2010 and 2012 with an early onset, alternating 
with outbreaks of lesser magnitude and later 
onset in other years.
Table 2. Complications during hospitalization, distribution 
by pathology
Complications during hospitalization (n= 1208)
 n %
Acute otitis media 300 24.8
Respiratory failure 302 25.0
Nosocomial infection 243 20.1
Persistent atelectasis 174 14.4
Sepsis 133 11.0
Pneumothorax 44 3.6
Effusion 12 1.0
Total number of complications  1208 100.0
Table 3. Analysis of risk factors associated with respiratory 
syncytial virus infection
Univariate analysis
Outcome measure RR 95% CI p
Malnutrition 0.85 0.79-0.92 < 0.01 
History of prior hospitalization 
due to a respiratory cause 0.81 0.78-0.84 < 0.01 
Immunosuppression 0.81 0.71-0.92 < 0.01 
Bronchiolitis as clinical  
presentation 1.11 1.08-1.14 < 0.01 
Age <3 months old 1.16 1.13-1.19 < 0.01 
Acute condition in individuals 
with whom the patient  
had contact 1.04 1.02-1.07 < 0.01 
Hypoxemia 1.14 1.07-1.22 < 0.01 
Use of bronchodilators 1.25 1.09-1.45 < 0.01 
Prematurity 0.90 0.86-0.94 < 0.01 
History of perinatal  
respiratory conditions 0.88 0.84-0.93 < 0.01 
Antibiotic use during  
hospitalization 0.89 0.87-0.92 < 0.01
Multivariate analysis
Outcome measure OR IC 95% p
Bronchiolitis as clinical  
presentation 1.54 1.32-1.79 < 0.01 
Age <3 months old 2.80 2.14-3.67 < 0.01 
Hypoxemia 1.84 1.42-2.37 < 0.01
first described inBuenos Aires in 1999, was the 
most commonly observed genotype within this 
subtype in the studied population.19,20 With regard 
to genotypes identified in subtype A, GA2 and 
GA5 were observed to circulate concurrently, 
particularly in the 2000-2008 period, while a new 
genotype emerged in 2009, called NA1, which 
was highly related to GA2 and finally displaced 
it in the subsequent years. It is worth noting 
that in 2012, a subtype A strain of RSV started 
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According to data collected on the annual 
hospital incidence rate of bronchiolitis at our 
site, 41% of cases were caused by RSV, consistent 
with several studies conducted in children 
younger than 5 years old hospitalized due to 
ALRTIs.1 Bronchiolitis as the most common 
clinical presentation was predominant in infants 
aged 6 to 9 months old, with an incidence peak 
between 2 and 7 months old; these findings have 
also been described by international studies.28-30 
In our series, 60.7% of infants had bronchiolitis 
at the time of admission, while the remaining 
39.3% had pneumonia. It should be noted that 
viruses account for the most common cause of 
community-acquired pneumonia, especially in 
children younger than 2 years old.1, 2
The population considered to be at a high 
risk is  made up of children with chronic 
pulmonary disease, congenital heart disease, and 
prematurity, all of whom have a higher risk of 
hospitalization than the general population.In 
agreement with our results, it has been observed 
that 41.5% of children hospitalized with ALRTIs 
due to RSV had underlying conditions. The most 
common underlying conditions included chronic 
respiratory disease, congenital heart disease, 
prematurity, chronic neurological disease, 
malnutrition and immunosuppression.11 These 
data may be magnified because our hospital is a 
national referral center where help is sought for 
children with these conditions, and this may be 
considered one of the weaknesses of our study.
A fourth of  our populat ion had some 
complication, being acute otitis media (24.8%) 
and atelectasis (14.4%) the most common ones.
International studies have estimated that RSV is 
the main virus associated with acute otitis media 
in children31 and that a mixed viral-bacterial 
infection in the middle ear could worsen the 
course of such condition.32
The case fatality rate for RSV in infants 
younger than 1 year old was estimated at 0.7% 
(0.3-4.8) among healthy children in industrialized 
countries, and at 2.1% (1.6-2.2) among children 
born in low income settings, which is consistent 
with results obtained in our study (case fatality 
rate: 1.9%).33 
Lastly, intrafamilial transmission of RSV 
described here gains significance because it 
reaches up to 46% of transmission among 
household members and a 27% incidence of 
secondary cases.1 This is related to our study 
finding that almost half of patients referred to 
have been in contact with household members 
who were acutely-ill or in close contact with these 
individuals.
Several vaccines have been introduced in 
the national immunization schedule to reduce 
ALRTIs burden, such asBordetella pertussis 
(included in the triple bacterial vaccine, the 
pentavalent or hexavalent vaccines), influenza 
and Streptococcus pneumoniae. These vaccines have 
had a remarkable impact, although immunization 
coverage still needs to be adjusted in different 
jurisdictions and departments.Unfortunately, a 
vaccine against RSV is still to be developed. At 
present, there are many lines of research that, 
if successful, would allow to administer the 
vaccine even during pregnancy, and thus prevent 
infections from occurring at a younger age.18 
In accordance to what has been described 
here, RSV could be referred to as one of the most 
clinically relevant viral agents in pediatrics.In the 
past decade, the most significant advance made 
in RSV prevention has been the development of 
palivizumab, a humanized monoclonal antibody 
that binds RSV F protein and prevents the 
adherence of the virus to the basal membrane 
of the respiratory epithelium. Palivizumab is 
exclusively indicated for preterm infants, infants 
younger than 2 years old with symptomatic 
bronchopulmonary dysplasia and/or congenital 
heart diseases, who account for the population 
at a high risk of suffering a severe form of these 
conditions, including death, due to RSV infection 
compared to infants who do not have such a 
history. The relevance of its use has been clearly 
demonstrated in this study in relation to the 
risk observed in patients with these underlying 
conditions.1,34 
Undoubtedly, the impact of RSV on the health 
system and the general population is greatly 
significant. Knowing these data will allow to 
adjust patient diagnostic and follow-up patterns 
and health policies to be implemented.It is 
essential to facilitate patient referral strategies so 
that patients are transferred and seen at tertiary 
care facilities, thereby reducing morbidity and 
mortality of the most vulnerable patients while 
an effective vaccine is developed.
CONCLUSIONS
In our study, RSV was the predominant 
agent in every year of the study period, with 
a seasonal epidemic pattern (May through July). 
RSV was associated with infants younger than 
3 months old with bronchiolitis and hypoxemia 
at the time of hospital admission. n
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